Bevacizumab (Avastin) eye drops inhibit corneal neovascularization

Bock, Felix; König, Yanyan; Kruse, Friedrich E.; Baier, Martin; Cursiefen, Claus

doi:10.1007/s00417-007-0684-4

Cited by 167 publications

(121 citation statements)

References 11 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…It has been reported that bevacizumab, ranibizumab, pegaptanib, and trastuzumab all have the ability to inhibit corneal neovascularization, and that bevacizumab is the most effective treatment in an experimental rat model (18) . Various experimental and clinical studies have reported that bevacizumab inhibits corneal neovascularization when used at different doses both topically and subconjunctivally (11)(12)(13) . In our comparison of topical and subconjunctival applications of bevacizumab, there were no statistical differences regarding the neovascularization score, the corneal neovascularization area, or the histopathological evaluation.…”

Section: Discussionmentioning

confidence: 99%

“…It has been approved as an antiangiogenic pharmaceutical for the treatment of certain cancers and it has also been utilized to treat ocular neovascularization (10) . In several studies it has been reported that topically or subconjunctivally applied bevacizumab results in the inhibition or regression of corneal neovascularization (11)(12)(13) . In this study we aimed to observe the effects of bevacizumab on experimentally produced corneal neovascularization in a rat model, and to compare the effects of this therapy when subconjunctivally or topically applied.…”

Section: Métodos: Córneas Direitas De 24 Ratos Wistar-albino Foram Camentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization

Özdemir¹,

Altıntaş²,

Altıntaş³

et al. 2014

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Purpose: To compare the effects of bevacizumab applied either subconjunctivally or topically, in a rat model of corneal neovascularization induced by alkali burn. Methods: The right corneas of 24 Wistar-Albino rats were cauterized with silver nitrate sticks. The rats were divided randomly and equally into three groups: no treatment control (n=8), subconjunctival bevacizumab treatment (n=8), and topical bevacizumab treatment (n=8). Immediately following cauterization, the subconjunctival group was treated with a 0.05 ml (1.25 mg) bevacizumab subconjunctival injection. The topical group was treated with 10 mg/ml bevacizumab twice daily, and the control group received subconjunctival saline injections twice daily. The burn stimulus and neovascularization scores were evaluated using a technique previously described by Mahoney and Waterbury. Digital photographs were obtained before the eyes were enucleated and corneal sections were then analyzed by histopathology. Results: The mean burn stimulus score was 1.86 ± 0.6 and there was no statistical difference between the groups (p=0.730). The mean neovascularization scores in the subconjunctival and topical bevacizumab groups were statistically lower than the control group (p<0.05). The mean percentage area of corneal neovascularization was 82.5 ± 22.1 in the control group, 42.7 ± 15.0 in the subconjunctival group, and 55.8 ± 18.2 in the topical group. The differences between the control and treatment groups were statistically significant (p<0.05). Histopathology showed that the treatment groups presented less neovascularization, inflammation, and fibroblast activity than the control group (p<0.05). Conclusions: This study demonstrates that both subconjunctival and topical administrations of bevacizumab inhibit corneal neovascularization and decrease inflammation and fibroblast activity in a rat model of corneal neovascularization induced by alkali burn.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Métodos: Córneas Direitas De 24 Ratos Wistar-albino Foram Camentioning

confidence: 99%

Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization

Özdemir¹,

Altıntaş²,

Altıntaş³

et al. 2014

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

show abstract

“…No serious adverse events were reported. 4,5 In another small masked study involving 10 subjects with corneal vascularisation who received bevacizumab injections, a 29 per cent decrease in vascularisation was observed. 6 Further larger studies are needed to fully evaluate the long-term effects of this novel treatment.…”

Section: Avastin Treatment For Corneal Neovascularisationmentioning

confidence: 98%

Ocular therapeutics

Albietz¹,

Napper²

2008

Clinical and Experimental Optometry

View full text Add to dashboard Cite

Adherence in glaucomaCorrect use of medications has always been a problem, especially in chronic diseases. A new study using electronic monitoring of drug-bottle opening as an objective measurement of adherence in medical glaucoma management has confirmed the already widely accepted clinical impression that more complex glaucoma topical medication dosing regimens result in poorer adherence. Previously the term 'compliance' was used but 'adherence' is now considered a more appropriate term. Two populations of primary open angle glaucoma subjects were examined: those using monotherapy (once-daily prostaglandin analogues n = 31) and those requiring an adjunctive medicine to the prostaglandin analogue (two-drug group n = 31). The main outcome measures were dosing errors (number of underadherence or over-adherence events) and coverage (proportion of pharmacologic duration covered by dosing) relative to the prescribed regimen. Adherence to the prostaglandin once daily was good in both groups by all measures (less than 10 per cent of subjects with more than five dosing errors and mean coverage of 97.2 Ϯ 6.1 per cent). Adherence to the second medication in the two-drug group was poorer (37 per cent of subjects with more than five dosing errors and mean coverage of 85.6 Ϯ 12.6 per cent). For the subjects using beta-blockers, 24.8 Ϯ 18.4 per cent of doses were taken at less than 10-hour intervals (over-adherence).Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: Objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007; 144: 533-540. Topical insulin improves corneal healing in diabetesCorneal epithelial healing can be a significant problem among diabetic patients. A recent study using a rat model with diabetes mellitus has shown that topical application of insulin normalised delayed corneal wound healing. The method involved creating a five-millimetre corneal abrasion, which was treated topically for seven days (four times daily) with 1, 2, or 5 U of insulin or with sterile vehicle.After seven days, residual corneal epithelial defects of rats with diabetes receiving the sterile vehicle were approximately 35 per cent larger than in healthy (nondiabetic) rats receiving the sterile vehicle. Diabetic rats receiving topical insulin had wounds ranging from 19 to 60 per cent smaller than diabetic rats not receiving topical insulin, similar to wound sizes in healthy rats. Topical insulin had no effect on re-epithelialisation of corneal wounds in healthy rats, corneal thickness, intraocular pressure or serum glucose level. The corneal sensitivity of diabetic rats was markedly reduced from healthy rats but rats with diabetes given insulin had corneal sensitivity values comparable to the healthy rats. DNA synthesis in the corneal epithelium was decreased in rats with diabetes but was comparable to that in healthy rats after they received topical insulin. Apoptosis and necrosis levels were similar in all healthy rats, diabetic rats treated with insulin and untreated diabetic...

show abstract

“…Dastjerdi i suradnici bilježe smanjenje za 47,1 % u srednjem neovaskularnom području i smanjenje kalibra žila za 54,1 % u 10 očiju 10 pacijenata koji su tretirani 1 % topičkim bevacizumabom tijekom 3 tjedna i praćeni 24 mjeseca 12 . Bock i suradnici agresivni NV liječili su topičkom primjenom 5 mg/ml bevacizumaba 5 puta dnevno, tijekom 0,5 -6 mjeseci s regresijom NV-a kod svih pacijenata 8 . Topički bevacizumab je djelotvoran kao neoadjuvantna (reduktivna) terapija uz kiruršku eksciziju u liječenju skvamozne neoplazije rožnice i konjunktive.…”

Section: Uvodunclassified

Bevacizumab and corneal pathology

Babić

Merlak

2017

Med. flum.

View full text Add to dashboard Cite

Sažetak. Cilj rada je dati pregled postojeće literature o terapiji bevacizumabom u liječenju neovaskularnih poremećaja rožnice. Rožnica je jedinstveno tkivo zbog svoje prirodne avaskularnosti. Imunoprivilegirano je vezivno tkivo koje služi kao mehanička prepreka i prednja refraktivna površina oka. Krvnu opskrbu prima perilimbalnim cilijarnim arterijama. Neovaskularizacija (NV) rožnice je stanje koje obilježava patološko urastanje perilimbalnih krvnih žila u rožnicu, zbog kroničnog nedostatka kisika. Patološka stanja koja uzrokuju neoangiogenezu rožnice su kemijske ozljede, ishemija, infekcije, degeneracije, trauma i imunološki procesi. Abnormalne krvne žile uzrokuju stvaranje ožiljaka rožnice i kompromitiraju vidnu oštrinu. Neovaskularizacija rožnice nastaje kada je ravnoteža između pro-angiogenih i anti-angiogenih faktora narušena u korist pro-angiogenih molekula. Dosadašnji uobičajeni tretmani za liječenje NV-a rožnice imaju ograničenu kliničku djelotvornost jer ne ciljaju molekularne posrednike angiogeneze. VEGF-A (engl. Vascular Endothelial Growth Factor-A) je glavni regulator hemangiogeneze. Bevacizumab prepoznaje sve VEGF izoforme. Neovaskularna stanja rožnice koja se mogu liječiti bevacizumabom su: inflamatorna stanja, infekcije i traumatski/jatrogeni uzroci. Studije su pokazale djelomično smanjenje neovaskularizacija rožnice kroz topičku, subkonjunktivalnu i intrastromalnu primjenu bevacizumaba. Anti-VEGF terapija stvorila je ogromnu nadu za liječenje neovaskularizacije rožnice, no ona ima svoje granice u liječenju, a uspješnost liječenja ovisi o veličini ožiljka, trajanju bolesti i opsegu neovaskularizacija. Anti-VEGF terapija je posebno učinkovita ako se primijeni u ranoj fazi (prva 2 tjedna neoangiogeneze). Kontrolirane prospektivne studije potrebne su za uspostavu dugoročne sigurnosti i određivanje minimalne efektivne i maksimalne sigurnosne koncentracija bevacizumaba za liječenje NV-a prednjeg segmenta oka.Ključne riječi: bevacizumab; patologija rožnice; rožnica; vaskularni endotelni faktori rasta Abstract. The purpose of this paper is to present a review of the current literature on anti-vascular endothelial growth factor (anti-VEGF) bevacizumab therapy for corneal neovascular disorders. Cornea is unique avascular, immunoprivileged connective tissue that acts as transparent mechanical barrier and the anterior eye refractive surface. Corneal neovascularizations (NV) are caused by chronic corneal ischemia with pathological ingrowth of perylimbal blood vessels into the cornea. Abnormal blood vessels cause scarring of the cornea and compromise visual acuity. Pathological conditions that cause corneal neoangiogenesis are: chemical burns, ischemia, infections, degeneration, trauma and immune processes. Corneal neovascularization occurs because of corneal pro-angiogenic and anti-angiogenic factors disequilibrium. The former treatment of corneal NV does not target the molecular mediators of angiogenesis. VEGF-A is the main regulator of angiogenesis. Bevacizumab recognizes all VEGF isoforms. Studies have de...

show abstract

Bevacizumab (Avastin) eye drops inhibit corneal neovascularization

Abstract: Bevacizumab eye drops seem to inhibit corneal neovascularization without obvious corneal epithelial side-effects.

Cited by 167 publications

References 11 publications

Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization

Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization

Ocular therapeutics

Bevacizumab and corneal pathology

Contact Info

Product

Resources

About